Conference Call with Alembic Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alembic Pharmaceuticals announced Q1FY26 results Revenue increased by 10% to Rs 1,711 crore. EBITDA up by 20% to Rs 288 crore. EBITDA Margin at 17%. Profit Before Tax up by 21% to Rs 191 crore. Net Profit at Rs 154 crore up by 15%. Pranav Amin MD, Alembic Pharmaceuticals, said: We began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage. Result PDF